ImpediMed Limited (ASX:IPD) Announces Q3 Revenue and ARR Growth
ImpediMed Limited (ASX:IPD) reports record Q3 revenue and ARR growth, along with key operational and management developments.
Category: Healthcare
Mesoblast Limited (ASX:MSB) Announces Q3 2025 Highlights
Mesoblast Limited (ASX:MSB) reports Q1 2025 milestones, including the US launch of Ryoncil® and strong financial performance.
EMVision Medical Devices Limited (ASX:EMV) Launches Clinical Trial for emu™ Device
EMVision Medical Devices Limited (ASX:EMV) has commenced pivotal clinical trials for its emu™ brain scanner and announced successful device testing and robust cash reserves.
Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.
MedAdvisor Limited (ASX:MDR) Releases 3Q FY25 Financial Update
MedAdvisor Limited (ASX:MDR) reports a significant decrease in 3Q FY25 revenue, announces cost-cutting measures and strategic initiatives.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
InteliCare Holdings Ltd (ASX:ICR) Partners with mecwacare for AI Platform Trial at Trescowthick Centre
InteliCare Holdings Ltd (ASX:ICR) partners with mecwacare to trial its AI-driven platform at Trescowthick Centre, enhancing aged care services in Victoria.
4DMedical Limited (ASX:4DX) Reports 103% Revenue Growth and Strategic Milestones
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Zelira Therapeutics Ltd (ASX:ZLD) Boosts Financial Flexibility with R&D Refund and ATM Facility
Zelira Therapeutics (ASX:ZLD) enhances financial flexibility with a $1.15M R&D refund and a $1M ATM facility to support ongoing developments.
Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.